Draft:Rice Powell

Vifor Pharma to propose Dr Alexandre LeBeaut as Board member

Retrieved on: 
Tuesday, February 2, 2021
Biotechnology, Pharmaceutical, Health, Cardiology, Vifor Pharma, Bad Homburg vor der Höhe, Companies, Germany, Etienne Jornod, Draft:Rice Powell

Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.

Key Points: 
  • Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.
  • Jacques Theurillat, Chairman of Vifor Pharma, commented: We are very pleased to nominate Alexandre LeBeaut for election to the Vifor Pharma Group Board of Directors.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications

Retrieved on: 
Monday, November 9, 2020
Vifor Pharma, Companies, Industries, Business, Draft:Rice Powell

Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong, and Macau, for all ANG-3777 nephrology indications.

Key Points: 
  • Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong, and Macau, for all ANG-3777 nephrology indications.
  • This agreement highlights the leadership position that Vifor Pharma has developed in the nephrology space and the fact that it has become the company of choice for organizations committed to partnering innovative nephrology focused assets, said Stefan Schulze, Chief Executive Officer of Vifor Pharma.
  • Angion and Vifor Pharma will share responsibilities for regulatory filings in the licensed territories and Vifor Pharma will be responsible for all commercialization activities related to nephrology indications in all licensed territories.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).

Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus

Retrieved on: 
Tuesday, October 20, 2020
Biotechnology, Health, Pharmaceutical, Clinical trials, Managed care, Bad Homburg vor der Höhe, Vifor Pharma, Companies, Fresenius, Industries, Nephrology, Germany, Chronic kidney disease, Draft:Rice Powell

View the full release here: https://www.businesswire.com/news/home/20201019005725/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20201019005725/en/
    Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (i.v.
  • Korsuva) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.
  • With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal commercialization partner to bring i.v.
  • In May 2018, Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) signed an initial agreement that granted the rights to develop and commercialize i.v.

Vifor Pharma and Cara Therapeutics sign US license agreement for IV Korsuva™* to treat dialysis patients with pruritus

Retrieved on: 
Tuesday, October 20, 2020
Vifor Pharma, Bad Homburg vor der Höhe, Companies, Industries, Business, Draft:Rice Powell, Etienne Jornod

Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.

Key Points: 
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma and Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care).
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).
  • Pruritus has also been reported in patients with stage III-V CKD who are not on dialysis.

Fresenius Medical Care North America Partners with Livongo to Empower People with Chronic Kidney Disease

Retrieved on: 
Wednesday, October 7, 2020
Bad Homburg vor der Höhe, Fresenius, Germany, Medicine, Chronic kidney disease, Chronic condition, Calcium acetate/magnesium carbonate, Draft:Rice Powell

and MOUNTAIN VIEW, Calif., Oct. 7, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the nation's leading renal care company, today announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD).

Key Points: 
  • and MOUNTAIN VIEW, Calif., Oct. 7, 2020 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA) , the nation's leading renal care company, today announced an innovative partnership with Livongo Health, Inc., the leading Applied Health Signals company, to improve the lives and outcomes of people with late-stage chronic kidney disease (CKD).
  • "We are excited about our innovative partnership with Fresenius Medical Care North America to offer people living with chronic kidney disease a better care experience that is personalized to them and addresses all aspects of their health."
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Fresenius Health Partners (FHP), a division of Fresenius Medical Care North America (FMCNA), is committed to providing value based care services leveraging the comprehensive integrated network of FMCNA.

Vifor Pharma Group Announces Successful Sale of OM Pharma

Retrieved on: 
Friday, September 18, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Vifor Pharma, Companies, Industries, Business, Draft:Rice Powell, Etienne Jornod

Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd.

Key Points: 
  • Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd.
  • OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee

Retrieved on: 
Tuesday, September 1, 2020
Biotechnology, Pharmaceutical, Health, Vifor Pharma, Companies, Industries, Business, Draft:Rice Powell, Etienne Jornod

Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.

Key Points: 
  • Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020.
  • Stefan Schulze, CEO of Vifor Pharma Group comments; We are delighted that Gregory will join Vifor Pharma as President North America.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); Relypsa; and OM Pharma.
  • Vifor Pharma Group is listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Fresenius Medical Care North America Prepares Dialysis Patients as Hurricane Laura Approaches Gulf Coast

Retrieved on: 
Wednesday, August 26, 2020
Bad Homburg vor der Höhe, Medicine, Private providers of NHS services, Clinical medicine, Membrane technology, Fresenius, Societates Europaeae, Health care, Dialysis, Draft:Rice Powell, Calcium acetate/magnesium carbonate

WALTHAM, Mass., Aug. 26, 2020 /PRNewswire/ --Fresenius Medical Care North America (FMCNA), the nation's leading provider of dialysis products and services, has activated its national disaster response team to ensure continuity of care as Hurricane Laura bears down on the Gulf Coast in Texas and Louisiana.

Key Points: 
  • WALTHAM, Mass., Aug. 26, 2020 /PRNewswire/ --Fresenius Medical Care North America (FMCNA), the nation's leading provider of dialysis products and services, has activated its national disaster response team to ensure continuity of care as Hurricane Laura bears down on the Gulf Coast in Texas and Louisiana.
  • Fresenius Kidney Care has been ensuring patients receive treatment prior to the storm by extending hours or moving patients to other clinics outside the evacuated areas.
  • Fresenius Kidney Care, a division of Fresenius Medical Care North America (FMCNA), provides dialysis treatment and support services to more than 200,000 people with kidney disease every year whether in their own homes or at more than 2,400 facilities nationwide.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Fresenius Medical Care North America Launches TheHub Connected Health Platform

Retrieved on: 
Wednesday, October 30, 2019
Economy of Germany, Fresenius, Societates Europaeae, Companies, Industries, Ulf Mark Schneider, Draft:Rice Powell

WALTHAM, Mass., Oct. 30, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, has launched its new connected health platform called TheHub.

Key Points: 
  • WALTHAM, Mass., Oct. 30, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, has launched its new connected health platform called TheHub.
  • "This best-in-class solution offers a technology hub that improves the experience for patients and the entire care team," said Jeff Burbank, Chief Strategy and Transformation Officer for Fresenius Medical Care North America.
  • "This new suite of cloud applications is making our connected health technologies easier to use for providers and patients," said Dr. Robert Kossmann, Chief Medical Officer for Fresenius Medical Care North America.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.

Fresenius Medical Care North America Responds To Signing of AB 290 in California

Retrieved on: 
Monday, October 14, 2019
Fresenius Medical Care, Economy of Germany, Fresenius, Companies, Industries, Draft:Rice Powell, Ulf Mark Schneider

WALTHAM, Mass., Oct. 14, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, released the following statement in response to the signing of AB 290 in California:

Key Points: 
  • WALTHAM, Mass., Oct. 14, 2019 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the nation's leading provider of kidney care products and services, released the following statement in response to the signing of AB 290 in California:
    "Fresenius Medical Care North America (FMCNA) is deeply saddened by Governor Newsom's decision to sign AB 290.
  • We stand ready to support these patients and continue to provide superior dialysis care both in-center and at home.
  • Fresenius Medical Care North America (FMCNA) is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions.
  • Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs and urgent care centers, Fresenius Medical Care North America provides coordinated healthcare services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent.